OSCR
Oscar Health, Inc.
OSCR has the edge over TNDM overall, supported by stronger fundamentals and lower modeled downside.
TNDM
Tandem Diabetes Care, Inc.
TNDM offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
TNDM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Strong |
TNDM's revenue and balance sheet are currently healthy, and its profitability is stable, but its cash flow is under pressure.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
TNDM PE Valuation
TNDM has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
TNDM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect TNDM's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over TNDM on earnings quality, reporting a profit while its opponent remains loss making.
TNDM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.72 | +$2.33 |
| Q2 2026 | -$0.93 | +$2.16 |
| Q1 2026 | -$1.40 | +$1.38 |
| Q4 2025 | -$3.07 | -$1.61 |
| Q3 2025 | -$3.05 | -$1.12 |
| Q2 2025 | -$3.09 | -$1.00 |
| Q1 2025 | -$2.78 | -$0.61 |
| Q4 2024 | -$1.46 | +$1.98 |
TNDM is still losing money, but far less than before: $0.72 per share over the past year, against $3.48 at its worst in mid-2023.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over TNDM on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over TNDM on profitability, with a higher operating margin.
TNDM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $283.7M | +14% |
| Q2 2026 | $254.6M | +5.8% |
| Q1 2026 | $247.2M | +5.5% |
| Q4 2025 | $290.4M | +2.7% |
| Q3 2025 | $249.3M | +2.2% |
| Q2 2025 | $240.7M | +8.5% |
| Q1 2025 | $234.4M | +22% |
| Q4 2024 | $282.6M | +44% |
TNDM's revenue has grown year over year for 11 quarters in a row: $284M last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -0.8% | +8.3 points |
| Q2 2026 | -5.4% | +16 points |
| Q1 2026 | -7% | +45 points |
| Q4 2025 | 2.9% | +3.1 points |
| Q3 2025 | -9.2% | +1.5 points |
| Q2 2025 | -22% | -7.7 points |
| Q1 2025 | -52% | -30 points |
| Q4 2024 | -0.2% | +18 points |
TNDM's operating margin was −0.8% last quarter, up 8.3 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over TNDM on cash generation, producing positive trailing cash flow while its opponent burns cash.
TNDM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.5M | -232% |
| Q2 2026 | -$38.7M | -$23M |
| Q1 2026 | $4.8M | +$26M |
| Q4 2025 | $3.1M | -59% |
| Q3 2025 | $4.2M | -81% |
| Q2 2025 | -$15.7M | -$4M |
| Q1 2025 | -$21.2M | -$8.8M |
| Q4 2024 | $7.6M | +$20.1M |
TNDM's free cash flow was −$36M over the past year, against −$25M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
TNDM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +639K shares |
| 1 year | +3% | +2M shares |
| 3 years | +7% | +4.5M shares |
| 5 years | +7.5% | +4.9M shares |
| Available history | +19% | +11.1M shares |
TNDM has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | $30M |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
TNDM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2022 | -16.5x | Net Cash |
| Q1 2022 | -3.8x | Net Cash |
| Q4 2021 | -2.0x | Net Cash |
| Q3 2021 | -2.7x | Net Cash |
| Q2 2021 | -3.0x | Net Cash |
| Q1 2021 | -8.3x | Net Cash |
| Q4 2020 | -37.9x | Net Cash |
TNDM has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
TNDM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.4 | Neutral |
| Stochastic | 30.2 | Neutral |
TNDM's weekly RSI is 48 (neutral) and its Stochastic is 30 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
TNDM PE vs Healthcare Sector
| Metric | TNDM | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
TNDM has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over TNDM on trend strength, trading above more of its moving averages.
TNDM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $16.9 | 3.4% above |
| 20 week MA | $18.1 | 3.4% below |
| 50 week MA | $19.1 | 8.4% below |
| 100 week MA | $19.9 | 12% below |
| 200 week MA | $26.5 | 34% below |
TNDM has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 34% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over TNDM on returns for 2026, with the stronger performance.
TNDM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $60.2 | $93.9 | +56% |
| 2021 | $93.9 | $151.8 | +62% |
| 2022 | $151.8 | $42.0 | -72% |
| 2023 | $42.0 | $29.6 | -30% |
| 2024 | $29.6 | $36.9 | +25% |
| 2025 | $36.9 | $22.4 | -39% |
| 2026 YTD | $22.4 | $17.5 | -22% |
TNDM has finished lower in three of the last six years. It's down 22% so far in 2026.